ScoreWhy is Jiangxi Fushine Pharmaceutical Co., Ltd. ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 4.17%
- Poor long term growth as Net Sales has grown by an annual rate of -2.90% and Operating profit at -34.60% over the last 5 years
- The company is Net-Debt Free
2
With a growth in Net Profit of 692.07%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 2 consecutive quarters
- ROCE(HY) Highest at 0.18%
- RAW MATERIAL COST(Y) Fallen by -299.89% (YoY)
- NET SALES(Q) At CNY 357.76 MM has Grown at 20.76%
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 135.31%, its profits have risen by 99.1%
4
Market Beating performance in long term as well as near term
- Along with generating 135.31% returns in the last 1 year, the stock has outperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Jiangxi Fushine Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Jiangxi Fushine Pharmaceutical Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Jiangxi Fushine Pharmaceutical Co., Ltd.
73.16%
2.13
62.25%
China Shanghai Composite
0.9%
1.20
14.07%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-2.90%
EBIT Growth (5y)
-34.60%
EBIT to Interest (avg)
-1.93
Debt to EBITDA (avg)
2.87
Net Debt to Equity (avg)
0.58
Sales to Capital Employed (avg)
0.30
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.17%
ROE (avg)
2.55%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.95
EV to EBIT
284.73
EV to EBITDA
67.91
EV to Capital Employed
3.54
EV to Sales
9.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1.24%
ROE (Latest)
-0.11%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend42What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 121.73 MM
ROCE(HY)
Highest at 5.68%
DIVIDEND PAYOUT RATIO(Y)
Highest at 23.27%
RAW MATERIAL COST(Y)
Fallen by -191.75% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 2.32 times
DIVIDEND PER SHARE(HY)
Highest at CNY 2.32
NET SALES(Q)
Highest at CNY 530.49 MM
OPERATING PROFIT(Q)
Highest at CNY 172.97 MM
PRE-TAX PROFIT(Q)
Highest at CNY 110 MM
NET PROFIT(Q)
Highest at CNY 115.37 MM
EPS(Q)
Highest at CNY 0.21
-8What is not working for the Company
INTEREST(HY)
At CNY 23.33 MM has Grown at 15.38%
CASH AND EQV(HY)
Lowest at CNY 964.72 MM
Here's what is working for Jiangxi Fushine Pharmaceutical Co., Ltd.
Pre-Tax Profit
At CNY 110 MM has Grown at 26,175.47%
over average net sales of the previous four periods of CNY 0.42 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 115.37 MM has Grown at 8,123.6%
over average net sales of the previous four periods of CNY 1.4 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Operating Cash Flow
Highest at CNY 121.73 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Net Sales
At CNY 530.49 MM has Grown at 62.1%
over average net sales of the previous four periods of CNY 327.26 MMMOJO Watch
Near term sales trend is very positive
Net Sales (CNY MM)
Net Sales
Highest at CNY 530.49 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Operating Profit
Highest at CNY 172.97 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Pre-Tax Profit
Highest at CNY 110 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Highest at CNY 115.37 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY 0.21
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Debtors Turnover Ratio
Highest at 2.32 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Dividend per share
Highest at CNY 2.32
in the last five yearsMOJO Watch
Company is distributing higher dividend from profits generated
DPS (CNY)
Dividend Payout Ratio
Highest at 23.27%
in the last five yearsMOJO Watch
Company is distributing higher proportion of profits generated as dividend
DPR (%)
Raw Material Cost
Fallen by -191.75% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Jiangxi Fushine Pharmaceutical Co., Ltd.
Interest
At CNY 23.33 MM has Grown at 15.38%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Cash and Eqv
Lowest at CNY 964.72 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Footer loading
